According to clinical and preclinical study results, incretin-based therapies may have a beneficial effect on hepatic steatosis and steatohepatitis, inhibit intestinal lipoprotein production, enhance β-cell function, and produce multiple biological actions in peripheral tissues [63, 64]. Here, GCG is linked to Hepatic steatosis.